Morgan Stanley Sellas Life Sciences Group, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,054,791 shares of SLS stock, worth $1.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,054,791

Previous 1,084,478 2.74%

Holding current value

$1.51 Million

Previous $2.38 Million 28.97%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.54 - $2.17 $45,717 - $64,420	-29,687 Reduced 2.74%	1,054,791 $1.69 Million
Q2 2025 Aug 15, 2025	BUY	$1.04 - $2.19 $1.06 Million - $2.23 Million	1,018,028 Added 1532.02%	1,084,478 $2.38 Million
Q1 2025 May 15, 2025	BUY	$0.92 - $1.62 $46,618 - $82,088	50,672 Added 321.16%	66,450 $71,000
Q4 2024 Feb 14, 2025	SELL	$0.84 - $1.35 $1,391 - $2,236	-1,657 Reduced 9.5%	15,778 $15,000
Q3 2024 May 14, 2025	BUY	$1.08 - $1.39 $15,269 - $19,651	14,138 Added 428.81%	17,435 $21,000
Q3 2024 Nov 14, 2024	BUY	$1.08 - $1.39 $15,269 - $19,651	14,138 Added 428.81%	17,435 $21,000
Q2 2024 May 14, 2025	SELL	$1.06 - $1.63 $13,229 - $20,344	-12,481 Reduced 79.1%	3,297 $3,000
Q2 2024 Oct 17, 2024	BUY	$1.06 - $1.63 $1,989 - $3,059	1,877 Added 132.18%	3,297 $3,000
Q2 2024 Aug 14, 2024	BUY	$1.06 - $1.63 $1,989 - $3,059	1,877 Added 132.18%	3,297 $3,000
Q1 2024 Oct 17, 2024	SELL	$0.51 - $1.55 $957 - $2,909	-1,877 Reduced 56.93%	1,420 $1,000
Q4 2023 Aug 16, 2024	SELL	$0.88 - $1.57 $1,651 - $2,946	-1,877 Reduced 56.93%	1,420 $1,000
Q4 2023 Feb 13, 2024	SELL	$0.88 - $1.57 $880 - $1,570	-1,000 Reduced 41.32%	1,420 $1,000
Q3 2023 Nov 15, 2023	SELL	$1.42 - $1.83 $8,520 - $10,980	-6,000 Reduced 71.26%	2,420 $3,000
Q2 2023 Aug 14, 2023	BUY	$1.35 - $1.8 $4,077 - $5,436	3,020 Added 55.93%	8,420 $13,000
Q1 2023 May 15, 2023	SELL	$1.18 - $3.86 $59,186 - $193,609	-50,158 Reduced 90.28%	5,400 $7,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $5.41 $3,839 - $11,539	2,133 Added 3.99%	55,558 $131,000
Q3 2022 Nov 14, 2022	SELL	$2.02 - $3.38 $76,852 - $128,595	-38,046 Reduced 41.59%	53,425 $108,000
Q2 2022 Oct 27, 2022	BUY	$2.14 - $4.15 $368 - $713	172 Added 0.19%	91,471 $204,000
Q2 2022 Aug 15, 2022	BUY	$2.14 - $4.15 $368 - $713	172 Added 0.19%	91,471 $204,000
Q1 2022 Oct 27, 2022	SELL	$4.73 - $7.18 $813 - $1,234	-172 Reduced 0.19%	91,299 $610,000
Q1 2022 May 13, 2022	SELL	$4.73 - $7.18 $155,309 - $235,755	-32,835 Reduced 26.45%	91,299 $610,000
Q4 2021 Feb 14, 2022	SELL	$5.36 - $9.53 $325,534 - $578,795	-60,734 Reduced 32.85%	124,134 $686,000
Q3 2021 Nov 15, 2021	BUY	$8.21 - $10.53 $1.52 Million - $1.95 Million	184,868 New	184,868 $1.69 Million

Others Institutions Holding SLS

# of Institutions

100

Shares Held

27.8M

Call Options Held

3.85M

Put Options Held

126K

View Full List

About SELLAS Life Sciences Group, Inc.

Ticker SLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,551,900
Market Cap $29.4M
Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...

More about SLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account